News >

Isatuximab Triplet Improves PFS in Relapsed/Refractory Myeloma

Gina Columbus @ginacolumbusonc
Published: Tuesday, Feb 05, 2019

John Reed, MD, PhD

John Reed, MD, PhD

Isatuximab in combination with pomalidomide (Pomalyst) and low-dose dexamethasone was shown to prolong progression-free survival (PFS) compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma, meeting the primary endpoint of the phase III ICARIA-MM trial (NCT02990338).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x